In 55 instances, a single proprietary (trade) name has been used to market у2 distinct generic anti-infective agents. In some cases, one trade name represents 2 different drugs in the same country-or even marketed by the same manufacturer. Some unrelated drugs and poisonous substances are also manufactured under trade names assigned to anti-infectives. The use of proprietary names in the prescribing of anti-infective drugs could result in considerable confusion or harm to patients.
A given drug may have у1 proprietary (trade) name. In some instances, hundreds of trade names are used for a single agent, with wide variability from country to country. As such, health care workers are often advised to issue only generic prescriptions to international travelers. A survey was undertaken to examine the additional possibility that a given trade name could denote 11 generic drug.
METHODS
During the period 1990-2006, an electronic listing of all anti-infective drugs was developed, and I have maintained it for the purpose of updating an infectious diseases web site. Principal data sources include Martindale, The Complete Drug Reference [1] and repeated monitoring of the Web sites of commercial companies. Additional trade terms and the locations and names of drug manufacturers were abstracted from an online electronic database (Micromedix [http://www.micro medix.com]; Thomson Healthcare).
RESULTS
As of 2006, a total of 271 generic antiinfective agents were marketed under 9375 trade names. In 52 instances, the same brand name is being used for 2 different antibiotics, and in 3 instances, the same brand name is being used for 3 different antibiotics (table 1) . A given trade name may even represent 2 different drugs in the same country (e.g., Abiocef and Baxam). Indeed, some proprietary drugs have been used by a single manufacturer to market different agents in the same country (e.g., Cibramicina, Cilicef, and Penilevel) or separate countries (Clamoxyl and Mandol).
DISCUSSION
Because verification of the current status of all generic and proprietary drugs is beyond the scope of this review, it is possible that given trade names have been "retired" as the parent drugs are withdrawn from use, only to be sequentially applied to newer generic drugs. Even when drug names are recycled in this manner, prior uses would still persist in standard texts and in the memory of senior physicians.
With the advent of international travel and widespread movement of refugees and immigrants, a proprietary drug prescription issued in one country might be misinterpreted by health care workers in another. In many cases, trade names are similar, if not confusing. For example, Ibimicyn (author's emphasis) is one of many names for ampicillin in Italy, whereas Ibimycin is a doxycycline preparation sold in Thailand. A simple misreading of the word "Monocid" (cefonicid or clarithromycin) could result in a patient receiving Monocide (bioallethrin; Fischer, Israel), a pyrithroid insecticide. Similar examples include Celex, a trade name assigned to cephalexin (Millimed, Thailand) and clonixin (Farmo Quimica, Chile), a nonsteroidal anti-inflammatory drug; or Vermin, which might be dispensed as either piperazine citrate (Steger, Mexico) or as verapamil (Ratiopharm, Finland).
Perhaps the most extreme example of confusion in drug trade names is the marketing of rifampicin as Ricin by Atlantic (Hong Kong and Thailand). A traveler found to be transporting Ricin while boarding an airplane in Bangkok could encounter considerable inconvenience! Beyond considerations of cost and efficiency, the use of trade names in prescribing anti-infective drugs might result in confusion and even harm to the patient. The marketing of redundant trade names for drugs used in other medical specialties should be investigated. Presumably, the availability of electronic databases will prevent similar ambiguities as future drug trade names are generated. 
